GSK-1995057

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameGSK-1995057

Drug Alias NameGSK-1995057

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)

Mechanisms of ActionTumor necrosis factor receptor inhibitors

TargetsTumor necrosis factor receptor

Therapy Area/IndicationsRespiration Disorders

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited Kingdom

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesGlaxosmithkline Plc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGlaxosmithkline Plc

Active IndicationsN/A

Inactive IndicationsRespiration Disorders

Other Information

ATC CodeN/A